Director John M. Climaco filed a Form 4 with the SEC on November 19, 2026, disclosing the acquisition of stock options in Moleculin Biotech, Inc. (NASDAQ:MBRX) on November 17, 2026.
Key Highlights
- Transaction date: November 17, 2026, with 4,000 stock options (right to buy) acquired by director John M. Climaco.
- Exercise price: $6.83 per share, with an expiration date of November 17, 2036.
- Vesting condition: According to the filing, options vest on the earlier of November 17, 2027 or the date of the company's next annual meeting of shareholders, subject to continued board service.
- Grant purpose: The filing states the options "were issued in connection with the reporting person's Board of Director service to the Company."
- Resulting ownership: Following the transaction, Climaco beneficially owns 4,334 derivative securities (stock options) directly.
- Filing signed: By Jonathan Foster by Power of Attorney, dated November 19, 2026.
Director Climaco's November 2026 Option Grant Details
According to the Form 4 filed with the SEC, John M. Climaco, a director of Moleculin Biotech, Inc. (NASDAQ:MBRX), acquired 4,000 stock options on November 17, 2026. The options carry an exercise price of $6.83 and are set to expire on November 17, 2036. The filing notes that the grant was made in connection with Climaco's service on the company's Board of Directors.
The filing discloses a specific vesting condition: the options vest "on the earlier of November 17, 2027 or the date of the Company's next annual meeting of shareholders, subject to the grantee's continued service on the Company's Board of Directors on the vesting date." No shares of non-derivative common stock were reported as acquired or disposed of in this filing.
Following this transaction, the filing reports that Climaco directly holds 4,334 stock options in total. The Form 4 was filed on November 19, 2026, and was signed by Jonathan Foster by Power of Attorney on behalf of the reporting person. No transaction code indicating a Rule 10b5-1 plan was checked in the filing.
What Was Disclosed
Moleculin Biotech director John M. Climaco disclosed the acquisition of 4,000 stock options at an exercise price of $6.83, granted November 17, 2026 in connection with board service, bringing his total directly held options to 4,334.


Please wait processing your request...